Geron(NASDAQ) GERN

Geron Corporation creates medicines for blood cancer patients. Its main drug helps people who need regular blood transfusions. The company focuses on stopping cancer cells from multiplying.

Fighting Cancer at the Source

• RYTELO (imetelstat): A drug that blocks an enzyme cancer cells use to live and divide; accounts for nearly all revenue.
• Myelodysplastic Syndromes Treatment: Therapy for patients whose bone marrow fails to produce enough healthy blood cells; serves the lower-risk patient segment.
• Clinical Pipeline: Research programs testing treatments for other blood cancers like myelofibrosis and acute myeloid leukemia.

Building a Global Cancer Brand

• Launched RYTELO in the U.S. in June 2024 following approval from the Food and Drug Administration.
• Received marketing authorization from the European Commission in March 2025 for patients with specific blood disorders.
• Partnered with Tanner Pharma in 2025 to distribute the drug through global access programs.
• Entered a royalty agreement with Royalty Pharma in November 2024 to secure $125 million in upfront funding.
• Reduced the total workforce by approximately one-third in December 2025 to improve operational efficiency.

The Science Behind the Therapy

Geron utilizes Nobel Prize-winning science to target telomerase, which is an enzyme that helps cancer cells survive indefinitely. By blocking this enzyme, the company aims to allow the body to produce new healthy blood cells again.

A Look at the Books

• Product revenue reached $57.5 million in the second quarter of 2026, up 17% year over year.
• Net loss for the six-month period ended June 30, 2026, was $20.3 million, down 44% year over year.
• Cash and marketable securities totaled $326.9 million as of June 30, 2026.
• Total accumulated deficit reached $1.9 billion as of June 30, 2026, due to historical research costs.
• Gross-to-net adjustments for the second quarter of 2026 were 20.7% of gross product revenue.

The Final Word

Geron has evolved from a research-focused organization into a commercial-stage company with its first approved drug. Its future depends on successfully selling RYTELO globally while managing high development costs for new uses of the therapy.